We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Products

Pipeline

Our pipeline prioritizes BIOX-101, which has completed Phase 2a testing for patients with intracerebral hemorrhage (ICH) and has been granted Orphan Drug Designation (ODD) for ICH in the U.S. and in Europe. Bioxodes is planning to start a Phase 2b trial with BIOX-101 in ICH early in 2027.

Based on the unique mechanism of action of BIOX-101, and particularly its effect on neutrophils, we aim to build an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.